nHale, A New Ventilation Device for the Treatment of COVID-19 to Be Distributed Nationwide

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

December 23, 2020

nHale, is a non-invasive respiratory support device authorized for the treatment of COVID-19 patients in the hospital, spaces converted for the treatment of COVID-19 patients, and in the private home. Solutions in Critical Care (SCC) has partnered with Nanotronics Health, LLC, to distribute nHale.

The new agreement allows for Nanotronics Health, LLC, to work with a leading distributor to deliver affordable and easy-to-use respiratory support devices for hospital systems within the United States that are experiencing surging COVID-19 patients.

Non-invasive ventilation is critical for COVID-19 patient care in the hospital and beyond. To meet this need, Nanotronics Health, LLC, leveraged Nanotronics’ deep in-house expertise, incorporating advanced AI, Intelligent Factory Control (IFC) and sophisticated engineering to conceive, design and manufacture nHale™ in under 90 days. The incorporation of IFC enables optimized manufacturing efficiency and the ability to scale production quickly while also avoiding a complex global supply chain. The quick production allows for healthcare providers to rely on Nanotronics Health, LLC, for cost-effective respiratory support devices for the treatment of COVID-19 patients.

“We are pleased to partner with an established distributor who understands the need to deliver accessible devices to patients and healthcare professionals when they need it,” said Julie Orlando, President of Nanotronics Health, LLC. “As hospitals continue to be strained throughout the country, it is our hope that we can provide a solution to both ease that strain while also providing reliable at-home support.”

SCC is a national network of well-established specialty distribution partners in the medical device industry. With eight distribution partners across the U.S., SCC offers medical device manufacturers a national strength with a local sales presence to grow their product line. “We intentionally choose products and companies that will make an impact and nHale™ is a much-needed disruption in the single bi-level system space,” says John Marmo, President of Solutions in Critical Care. “We look forward to bringing this and other critical care products to the forefront through our partnership with Nanotronics Health.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.